肠道微生态与造血干细胞移植相关性中国专家共识

摘要/Abstract

中国抗癌协会肿瘤与微生态专业委员会. 肠道微生态与造血干细胞移植相关性中国专家共识[J]. 国际肿瘤学杂志, 2021, 48(3): 129-135.

参考文献45

[1]	Chatterjee A, Modarai M, Naylor NR, et al. Quantifying drivers of antibiotic resistance in humans: a systematic review[J]. Lancet Infect Dis, 2018,18(12):e368-e378. DOI: 10.1016/S1473-3099(18)30296-2. pmid:30172580
[2]	Reinhardt C. The microbiota: a microbial ecosystem built on mutua-lism prevails[J]. J Innate Immun, 2019,11(5):391-392. DOI: 10.1159/000501237. pmid:31220850
[3]	Noor F, KaysenA, WilmesP, et al. The gut microbiota and hematopoietic stem cell transplantation: challenges and potentials[J]. J Innate Immun, 2019,11(5):405-415. DOI: 10.1159/000492943. pmid:30286447
[4]	Koliarakis I, Psaroulaki A, Nikolouzakis TK, et al. Intestinal microbiota and colorectal cancer: a new aspect of research[J]. J BUON, 2018,23(5):1216-1234. pmid:30512251
[5]	肖俊娟, 毕振旺, 李岩. 肠道微生态与肿瘤免疫调节的相关研究[J]. 国际肿瘤学杂志, 2017,44(1):34-37. DOI: 10.3760/cma.j.issn.1673-422X.2017.01.009.
[6]	Storb R, Prentice RL, Buckner CD, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment[J]. N Engl J Med, 1983,308(6):302-307. DOI: 10.1056/NEJM198302103080602.
[7]	Jenq RR, Taur Y, Devlin SM, et al. Intestinal Blautia is associated with reduced death from graft-versus-host disease[J]. Biol Blood Marrow Transplant, 2015,21(8):1373-1383. DOI: 10.1016/j.bbmt.2015.04.016. pmid:25977230
[8]	郭智, 刘晓东, 杨凯, 等. allo-HSCT并使用高剂量环磷酰胺诱导免疫耐受治疗重型再生障碍性贫血[J]. 中华器官移植杂志, 2015,36(6):356-361. DOI: 10.3760/cma.j.issn.0254-1785.2015.06.008.
[9]	Xu L, Chen H, Chen J, et al. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology[J]. J Hematol Oncol, 2018,11(1):33. DOI: 10.1186/s13045-018-0564-x.
[10]	中华医学会血液学分会干细胞应用学组. 中国异基因造血干细胞移植治疗血液系统疾病专家共识(Ⅲ)——急性移植物抗宿主病(2020年版)[J]. 中华血液学杂志, 2020,41(7):529-536. DOI: 10.3760/cma.j.issn.0253-2727.2020.07.001.
[11]	Lindner S, Peled JU. Update in clinical and mouse microbiota research in allogeneic haematopoietic cell transplantation[J]. Curr Opin Hematol, 2020,27(6):360-367. DOI: 10.1097/MOH.0000000000000616.
[12]	Cario E. Toll-like receptors in the pathogenesis of chemotherapy-induced gastrointestinal toxicity[J]. Curr Opin Support Palliat Care, 2016,10(2):157-164. DOI: 10.1097/SPC.0000000000000202. doi:10.1097/SPC.0000000000000202pmid:26986508
[13]	Shimasaki T, Seekatz A, Bassis C, et al. Increased relative abundance of klebsiella pneumoniae carbapenemase-producing klebsiella pneumoniae within the gut microbiota is associated with risk of bloodstream infection in long-term acute care hospital patients[J]. Clin Infect Dis, 2019,68(12):2053-2059. DOI: 10.1093/cid/ciy796. pmid:30239622
[14]	Tanaka JS, Young RR, Heston SM, et al. Anaerobic antibiotics and the risk of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2020,26(11):2053-2060. DOI: 10.1016/j.bbmt.2020.07.011.
[15]	Weber D, Jenq RR, Peled JU, et al. Microbiota disruption induced by early use of broad spectrum antibiotics is an independent risk factor of outcome after allogeneic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2017,23(5):845-852. DOI: 10.1016/j.bbmt.2017.02.006.
[16]	Zajᶏc-Spychała O, Wachowiak J, Pieczonka A, et al. Bacterial infections in pediatric hematopoietic stem cell transplantation reci-pients: incidence, epidemiology, and spectrum of pathogens: report of the Polish Pediatric Group for Hematopoietic Stem Cell Transplantation[J]. Transpl Infect Dis, 2016,18(5):690-698. DOI: 10.1111/tid.12581.
[17]	Schuster MG, Cleveland AA, Dubberke ER, et al. Infections in hematopoietic cell transplant recipients: results from the organ transplant infection project, a multicenter, prospective, cohort study[J]. Open Forum Infect Dis, 2017,4(2):ofx050. DOI: 10.1093/ofid/ofx050.
[18]	Lin Z, Iqbal Z, Ortiz JF, et al. Fecal microbiota transplantation in recurrent clostridium difficile infection: is it superior to other conventional methods?[J]. Cureus, 2020,12(8):e9653. DOI: 10.7759/cureus.9653. doi:10.7759/cureus.9653pmid:32923252
[19]	Vaughn JL, Balada-Llasat JM, Lamprecht M, et al. Detection of toxigenic Clostridium difficile colonization in patients admitted to the hospital for chemotherapy or haematopoietic cell transplantation[J]. J Med Microbiol, 2018,67(7):976-981. DOI: 10.1099/jmm.0.000774.
[20]	Salamonowicz M, Ociepa T, Frᶏczkiewicz J, et al. Incidence, course, and outcome of Clostridium difficile infection in children with hematological malignancies or undergoing hematopoietic stem cell transplantation[J]. Eur J Clin Microbiol Infect Dis, 2018,37(9):1805-1812. DOI: 10.1007/s10096-018-3316-5. doi:10.1007/s10096-018-3316-5pmid:29978303
[21]	Zhou B, Yuan Y, Zhang S, et al. Intestinal flora and disease mutually shape the regional immune system in the intestinal tract[J]. Front Immunol, 2020,11:575. DOI: 10.3389/fimmu.2020.00575. doi:10.3389/fimmu.2020.00575pmid:32318067
[22]	Vobořil M, Brabec T, Dobeš J, et al. Toll-like receptor signaling in thymic epithelium controls monocyte-derived dendritic cell recruitment and Treg generation[J]. Nat Commun, 2020,11(1):2361. DOI: 10.1038/s41467-020-16081-3. doi:10.1038/s41467-020-16081-3pmid:32398640
[23]	Jang GY, Lee JW, Kim YS, et al. Interactions between tumor-derived proteins and Toll-like receptors[J]. Exp Mol Med, 2020,52(12):1926-1935. DOI: 10.1038/s12276-020-00540-4. doi:10.1038/s12276-020-00540-4pmid:33299138
[24]	Jonsson H, Hugerth LW, Sundh J, et al. Genome sequence of segmented filamentous bacteria present in the human intestine[J]. Commun Biol, 2020,3(1):485. DOI: 10.1038/s42003-020-01214-7.
[25]	Baumgartner A, Bargetzi A, Zueger N, et al. Revisiting nutritional support for allogeneic hematologic stem cell transplantation—a systematic review[J]. Bone Marrow Transplant, 2017,52(4):506-513. DOI: 10.1038/bmt.2016.310.
[26]	Liu P, Wang B, Yan X, et al. Comprehensive evaluation of nutritional status before and after hematopoietic stem cell transplantation in 170 patients with hematological diseases[J]. Chin J Cancer Res, 2016,28(6):626-633. DOI: 10.21147/j.issn.1000-9604.2016.06.09. doi:10.21147/j.issn.1000-9604.2016.06.09pmid:28174491
[27]	Ilett EE, Jørgensen M, Noguera-Julian M, et al. Associations of the gut microbiome and clinical factors with acute GVHD in allogeneic HSCT recipients[J]. Blood Adv, 2020,4(22):5797-5809. DOI: 10.1182/bloodadvances.2020002677. pmid:33232475
[28]	Fredricks DN. The gut microbiota and graft-versus-host disease[J]. J Clin Invest, 2019,129(5):1808-1817. DOI: 10.1172/JCI125797. doi:10.1172/JCI125797pmid:31042160
[29]	Yoshifuji K, Inamoto K, Kiridoshi Y, et al. Prebiotics protect against acute graft-versus-host disease and preserve the gut microbiota in stem cell transplantation[J]. Blood Adv, 2020,4(19):4607-4617. DOI: 10.1182/bloodadvances.2020002604. pmid:32991720
[30]	Kusakabe S, Fukushima K, Yokota T, et al. Enterococcus: a predictor of ravaged microbiota and poor prognosis after allogeneic hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2020,26(5):1028-1033. DOI: 10.1016/j.bbmt.2020.01.019. doi:10.1016/j.bbmt.2020.01.019pmid:32018061
[31]	Shono Y, van den Brink MRM. Gut microbiota injury in allogeneic haematopoietic stem cell transplantation[J]. Nat Rev Cancer, 2018,18(5):283-295. DOI: 10.1038/nrc.2018.10. doi:10.1038/nrc.2018.10pmid:29449660
[32]	Parco S, Benericetti G, Vascotto F, et al. Microbiome and diversity indices during blood stem cells transplantation—new perspectives?[J]. Cent Eur J Public Health, 2019,27(4):335-339. DOI: 10.21101/cejph.a5393.
[33]	Payen M, Nicolis I, Robin M, et al. Functional and phylogenetic alterations in gut microbiome are linked to graft-versus-host disease severity[J]. Blood Adv, 2020,4(9):1824-1832. DOI: 10.1182/bloodadvances.2020001531. doi:10.1182/bloodadvances.2020001531pmid:32353108
[34]	Tu S, Zhong D, Xie W, et al. Role of toll-like receptor signaling in the pathogenesis of graft-versus-host diseases[J]. Int J Mol Sci, 2016,17(8):1288. DOI: 10.3390/ijms17081288.
[35]	Zhang F, Zuo T, Yeoh YK, et al. Longitudinal dynamics of gut bacteriome, mycobiome and virome after fecal microbiota transplantation in graft-versus-host disease[J]. Nat Commun, 2021,12(1):65. DOI: 10.1038/s41467-020-20240-x. doi:10.1038/s41467-020-20240-xpmid:33397897
[36]	Ladas EJ, Bhatia M, Chen L, et al. The safety and feasibility of probiotics in children and adolescents undergoing hematopoietic cell transplantation[J]. Bone Marrow Transplant, 2016,51(2):262-266. DOI: 10.1038/bmt.2015.275. doi:10.1038/bmt.2015.275pmid:26569091
[37]	Han H, Yan H, King KY. Broad-spectrum antibiotics deplete bone marrow regulatory T cells[J]. Cells, 2021,10(2):277. DOI: 10.3390/cells10020277. doi:10.3390/cells10020277pmid:33573218
[38]	Blaser MJ. Antibiotic use and its consequences for the normal microbiome[J]. Science, 2016,352(6285):544-545. DOI: 10.1126/science.aad9358. pmid:27126037
[39]	Pession A, Zama D, Muratore E, et al. Fecal microbiota transplantation in allogeneic hematopoietic stem cell transplantation recipients: a systematic review[J]. J Pers Med, 2021,11(2):100. DOI: 10.3390/jpm11020100. doi:10.3390/jpm11020100pmid:33557125
[40]	Lee YJ, Arguello ES, Jenq RR, et al. Protective factors in the intestinal microbiome against clostridium difficile infection in recipients of allogeneic hematopoietic stem cell transplantation[J]. J Infect Dis, 2017,215(7):1117-1123. DOI: 10.1093/infdis/jix011. pmid:28498996
[41]	Schoemans HM, Lee SJ, Ferrara JL, et al. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & gui-dance for graft-versus-host disease assessment[J]. Bone Marrow Transplant, 2018,53(11):1401-1415. DOI: 10.1038/s41409-018-0204-7. doi:10.1038/s41409-018-0204-7pmid:29872128
[42]	Penack O, Marchetti M, Ruutu T, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematologicalmalignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation[J]. Lancet Haematol, 2020,7(2):e157-e167. DOI: 10.1016/S2352-3026(19)30256-X. doi:10.1016/S2352-3026(19)30256-Xpmid:32004485
[43]	Spindelboeck W, Schulz E, Uhl B, et al. Repeated fecal microbiota transplantations attenuate diarrhea and lead to sustained changes in the fecal microbiota in acute, refractory gastrointestinal graft-versus-host-disease[J]. Haematologica, 2017,102(5):e210-e213. DOI: 10.3324/haematol.2016.154351. doi:10.3324/haematol.2016.154351pmid:28154090
[44]	王倩, 符粤文, 王勇奇, 等. 粪菌移植治疗异基因造血干细胞移植后难治性腹泻四例报告并文献复习[J]. 中华血液学杂志, 2019,40(10):853-855. DOI: 10.3760/cma.j.issn.0253-2727.2019.10.011.
[45]	Webb BJ, Brunner A, Ford CD, et al. Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients[J]. Transpl Infect Dis, 2016,18(4):628-633. DOI: 10.1111/tid.12550. doi:10.1111/tid.12550pmid:27214585

肠道微生态与造血干细胞移植相关性中国专家共识

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献45

相关文章15

编辑推荐

Metrics

本文评价

[1]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇.信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[2]	严爱婷, 王翠竹, 刘春桂, 鲁小敏.卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[3]	邓隽军, 赵大勇, 李淼.免疫检查点抑制剂在非小细胞肺癌治疗中的不良反应及危险因素[J]. 国际肿瘤学杂志, 2023, 50(9): 564-568.
[4]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会.同步放化疗期间应用聚乙二醇化重组人粒细胞刺激因子中国专家共识（2023版）[J]. 国际肿瘤学杂志, 2023, 50(4): 193-201.
[5]	周婷, 徐少华, 梅林.贝伐珠单抗联合卡培他滨治疗晚期乳腺癌的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 144-149.
[6]	袁晓玢, 汪洋, 杨敏, 吴鹏翔, 沈知临, 马勇斌, 丁列明.恩沙替尼治疗ALK阳性非小细胞肺癌的真实世界临床安全性监测与评估[J]. 国际肿瘤学杂志, 2023, 50(3): 150-156.
[7]	曹晓辉, 于荭, 李万湖.基于CT的影像组学分析在预测和鉴别治疗相关性肺炎中的应用[J]. 国际肿瘤学杂志, 2023, 50(2): 107-111.
[8]	焦盼盼, 薛丽娟, 詹娟.免疫检查点抑制剂相关不良反应的危险因素与预测因素[J]. 国际肿瘤学杂志, 2023, 50(12): 739-744.
[9]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会.新型冠状病毒感染疫情背景下肿瘤患者放射治疗管理相关问题中国专家共识（2023版）[J]. 国际肿瘤学杂志, 2023, 50(10): 577-584.
[10]	卢鑫, 姜军.安罗替尼治疗晚期恶性肿瘤的近期疗效和安全性[J]. 国际肿瘤学杂志, 2022, 49(9): 572-574.
[11]	林榕生, 吴楚海, 郭颖梅, 王涛, 陈荣斌, 刘少琴, 甘兵.特瑞普利单抗联合贝伐珠单抗二线以上治疗MSI-H型转移性结直肠癌的疗效及安全性[J]. 国际肿瘤学杂志, 2022, 49(2): 100-105.
[12]	中国抗癌协会肿瘤与微生态专业委员会.肠道微生态与肿瘤治疗相关消化系统并发症管理中国专家共识[J]. 国际肿瘤学杂志, 2022, 49(12): 711-717.
[13]	中华医学会数字医学分会, 重庆市医学会放射肿瘤治疗学专业委员会, 重庆市中西医结合学会肿瘤放疗专业委员会, 重庆市抗癌协会肿瘤放疗专业委员会.鼻咽癌调强放疗靶区勾画重庆共识之原发灶与靶区设计[J]. 国际肿瘤学杂志, 2022, 49(12): 705-710.
[14]	黄华玉, 宋启斌, 龚虹云, 宋佳.接受胸部放疗和免疫治疗肺癌患者肺炎发生率及影响因素分析[J]. 国际肿瘤学杂志, 2022, 49(12): 718-723.
[15]	安江宏, 钱莘, 骆璞, 谭晓华.肠道微生态与肿瘤的诊断和治疗[J]. 国际肿瘤学杂志, 2021, 48(7): 436-440.